SCHEMBL5336529

SCHEMBL5336529

CC(C)(C)OC(=O)N1CCN(c2ccccc2Cn2cncn2)CC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MC4R P32245 1/20 0.54
SMARCA2 P51531 1/20 0.46
SMARCA4 P51532 1/20 0.46
PBRM1 Q86U86 1/20 0.46
KDM1A O60341 4/20 0.44
KDM1B Q8NB78 1/20 0.44
ACHE P22303 2/20 0.43
CKS1B P61024 1/20 0.43
SKP1 P63208 1/20 0.43
SKP2 Q13309 1/20 0.43
ALDH1A1 P00352 1/20 0.43
POLB P06746 1/20 0.43
MAPT P10636 1/20 0.43
GPR119 Q8TDV5 3/20 0.43
PLA2G7 Q13093 1/20 0.43
MGLL Q99685 1/20 0.43
ABHD6 Q9BV23 1/20 0.43
SCD O00767 1/20 0.42
SCD5 Q86SK9 1/20 0.42
KIT P10721 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7981893 0.81 GAA (0.56) SMARCA2SMARCA4PBRM1ACHECKS1B
SCHEMBL5340805 0.80 SMARCA2 (0.46) SMARCA2SMARCA4PBRM1KDM1AKDM1B
SCHEMBL5335315 0.80 MC4R (0.53) MC4RSMARCA2SMARCA4PBRM1ACHE
SCHEMBL5335100 0.79 PLA2G7 (0.61) MC4RSMARCA2SMARCA4PBRM1ACHE
SCHEMBL5338852 0.79 KDM1A (0.54) SMARCA2SMARCA4PBRM1KDM1AKDM1B
SCHEMBL615074 0.79 CHRM2 (0.52) SMARCA2SMARCA4PBRM1ACHECKS1B
SCHEMBL14355783 0.79 MC4R (0.50) MC4R
SCHEMBL5335298 0.78 MGLL (0.60) MC4RSMARCA2SMARCA4PBRM1CKS1B
SCHEMBL416461 0.78 ACHE (0.51) SMARCA2SMARCA4PBRM1ACHECKS1B
SCHEMBL110163 0.78 NCF1 (0.51) MC4RSMARCA2SMARCA4PBRM1ACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7291619-B2 Melanocortin receptor agonists ELI LILLY AND COMPANY (US) 2007-11-06 US disclosed
US-7291619-B2 Melanocortin receptor agonists ELI LILLY AND COMPANY (US) 2007-11-06 US disclosed
EP-1368340-B1 PIPERAZINE DERIVATIVES AS MELANOCORTIN RECEPTOR AGONISTS LILLY CO ELI (US) 2005-08-10 EP disclosed
US-20040092507-A1 Melanocortin receptor agonists ELI LILLY AND COMPANY 2004-05-13 US disclosed
EP-1368340-A1 PIPERAZINE DERIVATIVES AS MELANOCORTIN RECEPTOR AGONISTS ELI LILLY AND COMPANY (US) 2003-12-10 EP disclosed
WO-2002059108-A1 MELANOCORTIN RECEPTOR AGONISTS ELI LILLY AND COMPANY (US) 2002-08-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040092507-A1 Melanocortin receptor agonists MC1R, MC4R, MC5R MC4R 2/4885SMARCA2 4437/4885SMARCA4 4290/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.